Inozyme Pharma (INZY)
(Real Time Quote from BATS)
$4.52 USD
-0.08 (-1.74%)
Updated Jul 9, 2024 12:22 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INZY 4.52 -0.08(-1.74%)
Will INZY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INZY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INZY
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
Why Earnings Season Could Be Great for Inozyme (INZY)
INZY: What are Zacks experts saying now?
Zacks Private Portfolio Services
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
bluebird (BLUE) Up 101% in the Past Three Months: Here's Why
Other News for INZY
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
INZY Makes Bullish Cross Above Critical Moving Average
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
Inozyme initiated with bullish view at Wells Fargo, here's why